Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

112.30 +3.65 (+3.36%)
Streaming Delayed Price Updated: 11:29 AM EST, Nov 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership
BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost optimization. 
Via Benzinga
BioNTech SE (NASDAQ:BNTX) Reports Mixed Q3 2025 Results with Major Revenue Beat and Quarterly Loss
BioNTech Q3 2025: Revenue surges on a $1.5B partnership payment, but company posts a net loss. Full-year sales guidance was raised significantly. 
Via Chartmill
Earnings Scheduled For November 3, 2025
 
Via Benzinga
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers
As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Pfizer, BioNTech’s Updated COVID-19 Vaccine Shows Robust Immune Response In Late-Stage Study – More Details Inside
Via Stocktwits
What Analysts Are Saying About BioNTech Stock
 
Via Benzinga
Why Did BioNTech Stock Surge 10% Pre-Market Today?
Via Stocktwits
2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever
Both companies are monsters in their industry and are poised to thrive. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
Beyond The Numbers: 7 Analysts Discuss BioNTech Stock
 
Via Benzinga
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead
These biotechs could finally come into their own by the end of the decade. 
Via The Motley Fool
Topics Government World Trade
Healthcare Sector Shines Amidst Market Turbulence, Bolstering S&P 500 Resilience
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
Decoding Life's Blueprint: New Tech Maps RNA-Protein Interactions, Unlocking Disease Cures
A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human... 
Via MarketMinute
Topics Artificial Intelligence Derivatives
Why BioNTech Stock Jumped by Nearly 4% on Wednesday
The company's push deeper into a hot new technology, plus good news from a top collaborator, put the shine on its equity. 
Via The Motley Fool
Topics Artificial Intelligence Government World Trade
Why BioNTech Stock Bumped Higher Today
Investors were cheered by two pieces of good news concerning the biotech's most famous product. 
Via The Motley Fool
CDC Ends Universal Covid Vaccine Recommendation; Moderna Skids
Moderna stock toppled Friday after advisors to the CDC and Prevention ended the universal recommendation for Covid vaccines. 
Via Investor's Business Daily
The Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its Debut
The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters. 
Via Investor's Business Daily
Topics Government
Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax
Moderna's updated Spikevax shows strong antibody response and safety, targeting dominant COVID-19 variants like LP.8.1 in high-risk and older adults. 
Via Benzinga
Oracle Retreats, Fed Rate Cut Looms, and Vaccine Politics Shake Pharma Stocks
Markets closed Friday in mixed fashion as economic uncertainty and politics clashed with earnings optimism. Oracle's rollercoaster continues, RFK Jr. rattles vaccine makers, and the Fed appears poised... 
Via Chartmill
Topics Artificial Intelligence Economy
Synopsys, Chewy, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (Sep. 8- Sep. 12): Are The Others In Your Portfolio?
Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biotech trial updates and mixed analyst calls pressured others. 
Via Benzinga
Topics Earnings
Why BioNTech Stock Sank by More Than 7% Today
The type of vaccine it's most famous for might be cast in a very unflattering light in the very near future.. 
Via The Motley Fool
Topics Death Government
Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths
Shares of COVID-19 vaccine makers are trading lower Friday. Vaccine stocks fell Friday on a Washington Post report that Trump administration officials plan to link the shots to 25 child deaths. 
Via Benzinga
Topics Government
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults
Pfizer and BioNTech's LP.8.1 COVID-19 vaccine boosts antibodies 4-fold in high-risk adults, with no new safety concerns reported. 
Via Benzinga
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
BioNTech and Bristol Myers report strong interim results for pumitamig plus chemo in lung cancer, showing high response rates. 
Via Benzinga
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch
Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer. 
Via Investor's Business Daily
Why BioNTech Stock Crushed the Market Today
The company might be close to commercializing its most advanced pipeline program. 
Via The Motley Fool
Guidewire Software, Samsara, Zumiez And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Shots Fired! After RFK Jr.'s Senate Grilling, Will Pfizer, Moderna Survive The Battle In D.C.?
It's unprecedented times for the Covid vaccine market, experts say. And Pfizer and Moderna remain under significant pressure. 
Via Investor's Business Daily
BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb
The company's DualityBio-partnered drug met the pre-specified bar for success in a pivotal study. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.